Skip to main content

Table 1 Patient demographic and clinical characteristics

From: A new promising way of maintenance therapy in advanced ovarian cancer: a comparative clinical study

Characteristic Arm 1
(n = 46)
Arm 2
(n = 76)
Arm 3
(n = 42)
Arm 4
(n = 40)
Arm 5
(n = 80)
Age, years
 Median 54.0 54.0 54.5 54.2 54.1
 Range 40–76 43–71 41–68 47–68 39–69
Ethnicity, No. (%)
 White 42 (91.3) 68 (89.5) 38 (90.5) 36 (90) 73 (91.2)
 Asian 4 (8.7) 7 (9.2) 4 (9.5) 3 (7.5) 6 (7.5)
 Black 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
 Other 0 (0) 1 (1.3) 0 (0) 1 (2.5) 1 (1.2)
FIGO stage at screening, No. (%)
 III 38 (82.6) 60 (78.9) 34 (80.9) 32 (80.0) 66 (82.5)
 IV 8 (17.4) 16 (21.1) 8 (19.0) 8 (20.0) 14 (17.5)
PCI
 Median 24 27 27 27 29
 Range 9–36 8–37 7–37 7–37 7–37
  7–10 (≤ 10), No. (%) 2 (4.3) 4 (5.3) 4 (9.5) 2 (5.0) 2 (2.5)
  11–20 12 (26.1) 20 (26.3) 8 (19.0) 8 (20.0) 20 (25.0)
  21–30 23 (50.0) 26 (34.2) 14 (33.3) 17 (42.5) 26 (32.5)
  31–37 9 (19.6) 26 (34.2) 16 (38.1) 13 (32.5) 32 (40.0)
ECOG performance status at screening, No. (%)
 0 40 (87.0) 67 (88.2) 37 (88.1) 34 (85.0) 69 (86.3)
 1 3 (6.5) 5 (6.6) 3 (7.1) 4 (10.0) 6 (7.5)
 2 3 (6.5) 4 (5.3) 2 (4.8) 2 (5.0) 5 (6.3)
pa 0.96 0.84 0.86 0.93  
Rate of patients with ascites
 at screeningb, No. (%) 31 (67.4) 51 (67.1) 29 (69.0) 28 (70.0) 55 (68.8)
  95% CI 52–80 55–68 53–82 54–83 57–79
  pb 0.87 0.82 0.97 0.89  
Standard chemotherapy regimen, No. (%)
 ТР 26 (57) 40 (53) 20 (48) 18 (45) 37 (46)
 ТС 20 (43) 36 (47) 22 (52) 22 (55) 43 (54)
CA-125 level, U/mL
 at screening
  Mean 579.78 584.32 581.85 581.98 583.75
  Range 110- > 600 115- > 600 120- > 600 110- > 600 105- > 600
 at presurgery
  Mean ± SDc 31.50 ± 5.19 37.91 ± 21.43 42.26 ± 24.50 581.98 ± 85.07 68.70 ± 16.23
  Range 25–45 30–210 30–190 69- > 600 35–110
 after combined treatment
  Mean ± SDc 12.78 ± 2.78 10.42 ± 4.07 12.67 ± 5.48 31.05 ± 8.70 32.44 ± 6.23
  Range 10–20 8–42 8–35 20–54 20–55
Primary debulking surgery at combined treatmentd, No. (%)
 Complete cytoreduction (no visible tumor foci) 39 (84.8) 63 (82.9) 34 (81.0) 5 (12.5) 20 (25.0)
 Optimal cytoreduction (≤ 1 cm) 7 (15.2) 13 (17.1) 8 (19.0) 21 (52.5) 51 (63.8)
 Suboptimal cytoreduction (> 1 cm) 0 (0) 0 (0) 0 (0) 14 (35.0) 9 (11.3)
Disease progression (tumor recurrence rate) after combined treatment within five years of follow-up, No. (%) 38 (82.6) 61 (80.3) 33 (78.6) 38 (95.0) 78 (97.5)
Rate of patients without recurrent ovarian cancer within five years of follow-up, No. (%) 8 (17.4) 15 (19.7) 9 (21.4) 2 (5.0) 2 (2.5)
  1. FIGO International Federation of Gynecology and Obstetrics, PCI peritoneal cancer index, ECOG Eastern Cooperative Oncology Group, 95% CI 95% confidence interval, SD standard deviation
  2. aMann-Whitney U-test was applied to determine the differences between arms 1–4 vs arm 5
  3. bChi-square criterion was applied to determine the differences between arms 1–4 vs arm 5
  4. cStudent’s test was applied to determine mean level, standard deviation, and the differences between arms 1–3 vs arm 5
  5. All differences between arms 1–3 vs arm 5 were statistically significant (p <  0.0001)
  6. dMann-Whitney U-test was applied to compare the degree of surgery used in arms 1–3 vs arm 5. Degrees of surgery were scored as follows: macroscopic completed resection (no visible tumor foci) – 0, optimal debulking (≤ 1 cm) – 1, suboptimal debulking (> 1 сm) – 2. All differences between arms 1–3 vs arm 5 were statistically significant (p <  0.0001)